Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 15 | SFEBES2008 | Next issue

Society for Endocrinology BES 2008

Symposia

Recent advances and new treatment options in diabetes

ea0015s40 | Recent advances and new treatment options in diabetes | SFEBES2008

New approaches to treating diabetic microvascular complications

Malik Rayaz

The long-term microvascular complications of diabetes are a significant cause of morbidity and predict mortality in diabetic patients. Multiple pathways have been implicated in the pathogenesis of each of these complications. Evolving evidence suggests that early intervention may have long-term benefits in preventing development and reversing these chronic complications.A major limitation in the approach to dealing with the microvascular complications is...

ea0015s41 | Recent advances and new treatment options in diabetes | SFEBES2008

Incretin-based therapies

Bailey Clifford

The incretin concept refers to components of the entero-insular axis that enhance the insulin response to a meal. The incretin effect is mostly attributed to the gut hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). The incretin effect is reduced in type 2 diabetes, and this appears to be due largely to reduced secretion of GLP-1. GLP-1 increases glucose-stimulated insulin secretion by pancreatic β-cells, reduces glucagon sec...

ea0015s42 | Recent advances and new treatment options in diabetes | SFEBES2008

Immune therapy: prevention is better than cure

Roep Bart

Type 1 diabetes (T1D) is a T-cell mediated autoimmune disease in which the insulin-producing pancreatic beta-cells in the islets of Langerhans are destroyed. While the symptoms of the disease have become treatable to a certain extent, even intensive state-of-the-art insulin therapy cannot prevent the development of severe complications in the majority of patients. There is, therefore, a huge and unmet clinical demand for disease intervention, but a cure for T1D does not yet ex...

ea0015s43 | Recent advances and new treatment options in diabetes | SFEBES2008

Islet transplantation: way to go!

Shaw J

The DCCT conclusively confirmed that long-term microvascular complications of Type 1 diabetes can be prevented by restoration of near-normal glucose levels. Despite ongoing refinements in management including structured re-education, optimized insulin analogue regimens, continuous subcutaneous insulin infusion and even steps towards the bioartificial pancreas, exogenous insulin replacement is inextricably linked to risk of severe hypoglycaemia.Transplant...